Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
16.66
-1.24 (-6.93%)
At close: Dec 5, 2025, 4:00 PM EST
16.78
+0.12 (0.72%)
After-hours: Dec 5, 2025, 6:15 PM EST
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $351.00K in the quarter ending September 30, 2025.
Revenue (ttm)
$351.00K
Revenue Growth
n/a
P/S Ratio
429.39
Revenue / Employee
$3,408
Employees
103
Market Cap
150.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MCRB News
- 12 days ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 - GlobeNewsWire
- 7 weeks ago - Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - GlobeNewsWire
- 2 months ago - Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - GlobeNewsWire
- 2 months ago - More companies adopt co-CEO structure - Reuters